KCT0004280进行中（未招募）未知
The efficacy of hepatotonic drugs in several prescription patterns for the liver disease patients with elevated liver enzyme levels: a retrospective, comparative, phase ? study
Celltrion Pharm0 个研究点目标入组 906 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 906
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1. over 19 year old on the index date the first treated hepatotonic drugs
- •2. Subjects who were treated hepatotonic drugs for over then 12 weeks and meet the following criteria
- •1) Godex cap.: over then 168 cap/12 weeks
- •2) Ursa tab.: over then 16,800 mg/12 weeks
- •3) Legalon cap.: over then 168 cap/12 weeks
- •4) Pennel cap.: over then 168 cap/12weeks
- •3. outpatient
- •4. Subjects who meet the hepatic function index (40 IU/L = ALT = 400 IU/L and AST = 400 IU/L)
排除标准
- •1) Subjects with hepatic cirrhosis or malignancy
- •2) Subjects with HBV, HCV(who weren’t treated anti-virus therapy, could be included)
- •3) Subjects who administered hepatotonic drugs within 14 days of the index date
- •4) Other subjects who are not eligible for this study
研究者
相似试验
已完成
不适用
Comparison of efficacy for suppression of hepatocellular carcinoma after antiviral treatment between interferon beta and ribavirin treatment and pegylated interferon alpha and ribavirin treatmentChronic hepatitis CJPRN-UMIN000016070Department of General Internal Medicine, Kyushu University Hospital800
招募中
不适用
The efficacy of hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic pegylated interferon alpha-2b for advanced intrahepatic cholangiocarcinomaadvanced intrahepatic cholangiocarcinomaJPRN-UMIN000007303Iwate Medical University50
招募中
不适用
Inhibitory effect of therapeutic medicine on liver disease progression in metabolic dysfunction-associated fatty liver disease patientmetabolic dysfunction-associated fatty liver diseaseJPRN-UMIN000044364Department of Gastroenterology, Hokkaido University Hospital500
已完成
2 期
The effect of hepatoheal tablet on non alcoholic fatty livernon alcoholic fatty liver.Nonalcoholic fatty liver disease (NAFLD)IRCT2014042612438N6Barij Research Center of Medicinal Herbs90
已完成
1 期
Hepatic Impairment Study With MDV3100 in Subjects With Mild and Moderate Hepatic Impairment Compared to a Healthy Control GroupPharmacokinetics of MDV3100Healthy SubjectsKidney DiseasesNCT01901133Astellas Pharma Europe B.V.33